Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

To join this study, you would need to have been diagnosed with 'limited-stage small cell lung cancer' (meaning it hasn't spread widely). You must have recently completed a course of chemotherapy along with radiotherapy (within 1 to 42 days before starting the study treatment), and your cancer must not have worsened after these treatments. The chemotherapy you received must have included platinum and etoposide, and the radiotherapy would have been given over about 3 to 6 weeks.

There are also some general health requirements: you should have a good level of physical fitness (a score of 0 or 1 on a scale called ECOG, which your doctor can explain) and a life expectancy of at least 12 weeks. Sometimes, a preventive brain radiation (PCI) might be given, and if so, this needs to have been completed before the study drug starts.

However, you wouldn't be able to join if your cancer has already spread widely ('extensive-stage SCLC'), or if you have certain other health conditions like active autoimmune diseases, uncontrolled illnesses like severe lung problems, or ongoing infections such as tuberculosis, HIV, or hepatitis. This study is not for people who had their chemotherapy and radiotherapy separated, meaning they didn't happen at the same time.

If you join this study, you'll be assigned to receive one of the study drugs or a placebo, like a sugar pill, without you or your doctor knowing which one initially. You'll need to visit the hospital regularly for check-ups, blood tests, and scans to see how you're responding to the treatment and to monitor for any side effects. These visits will be more frequent at the start and then become less often over time.

The treatment itself will involve receiving medication, which might be given through an IV drip or as tablets, depending on the specific drug. The total duration of the investigational treatment will vary for each participant, but there will be a follow-up period, possibly for several years, even after you stop receiving the study drug. This is to keep an eye on your long-term health and the lasting effects of the treatment. Your participation involves attending all scheduled appointments and reporting any changes in your health to your study team.